A STAT chat with Lilly's CSO
Matthew Herper will sit down tomorrow with Eli Lilly's chief scientific officer, Daniel Skovronsky, in a STAT+ Conversation. There's plenty to talk about.
Lilly was the first to enter an antibody treatment for Covid-19 into human clinical trials earlier this summer, and its rheumatoid arthritis drug baricitinib is being tested by the National Institutes of Health in patients with the disease. It recently unveiled a new strategy, built around its acquisition of Loxo Oncology, for developing new cancer drugs. And it's always interesting to ask Skovronsky, the founder of Lilly acquisition target Avid Radiopharmaceuticals, about Alzheimer's disease and abotu the place of entrepreneurship in biotech.
Subscribers should have already received signup information. Click here for details on STAT Plus.
Lilly was the first to enter an antibody treatment for Covid-19 into human clinical trials earlier this summer, and its rheumatoid arthritis drug baricitinib is being tested by the National Institutes of Health in patients with the disease. It recently unveiled a new strategy, built around its acquisition of Loxo Oncology, for developing new cancer drugs. And it's always interesting to ask Skovronsky, the founder of Lilly acquisition target Avid Radiopharmaceuticals, about Alzheimer's disease and abotu the place of entrepreneurship in biotech.
Subscribers should have already received signup information. Click here for details on STAT Plus.
No hay comentarios:
Publicar un comentario